Irritable bowel syndrome.
Irritable bowel syndrome (IBS) is one of the most common 'functional' gastrointestinal disorders accounting for 3% of all primary care consultations, with a strong female predominance. Although most of the literature comes from Western industrialized societies, when it has been looked for, this disorder appears to be equally common in the Third World. It is characterized by chronic abdominal pain or discomfort associated with disordered bowel habit and visceral hypersensitivity. Anxiety and somatization are more common in IBS than in the general population and may encourage consultation; however, they correlate poorly with symptoms. Bacterial gastroenteritis may be followed by the development of IBS in 5-10% of patients, depending on the severity of initial illness and prior anxiety or depression. The Rome criteria allow reliable diagnosis provided that there are no 'alarm' features which mandate further investigation. Microscopic colitis and bile salt malabsorption can easily be mistaken for IBS, as can chronic infestations or infections which should be considered, while recognizing that these are extremely uncommon in westernized societies. Some patients respond to exclusion diets as lactose and wheat intolerance are common. Others with prominent anxiety and/or depression respond to psychotherapy or antidepressants. Diarrhoeal symptoms respond to loperamide and 5HT3 receptor antagonists, while constipation responds to 5HT4 agonists. Antispasmodics may have limited benefit in treating pain. Low-dose tricyclic antidepressants are also helpful in alleviating pain and anxiety, even in those without obvious psychiatric disorders. If diagnostic criteria are met, then once diagnosed, new diagnoses rarely appear.
Spiller
Robin C
RC
Wolfson Digestive Diseases Centre, University Hospital, Nottingham, NG7 2UH, UK. robin.spiller@nottingham.ac.uk
D003937:Diagnosis, Differential; D004361:Drug Tolerance / Q000502:physiology; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000150:complications; D043183:Irritable Bowel Syndrome / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D011379:Prognosis; D011788:Quality of Life; D018490:Serotonin Agents / Q000627:therapeutic use
D018490:Serotonin Agents